BeOne Medicines (BEIGF) Non-Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Non-Current Assets data on file, last reported at $2.0 billion in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $2.0 billion, changed 0.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (changed 0.38% YoY), and the FY2025 annual result was $2.0 billion, up 1.33% from the prior year.
• Non-Current Assets was little changed at $2.0 billion in Q1 2026 per BEIGF's latest filing, from $2.0 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $2.0 billion in Q2 2025 and troughed at $976.8 million in Q3 2022.
• A 5-year average of $1.6 billion and a median of $1.8 billion in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets surged 57.82% in 2022, then climbed 0.38% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $1.2 billion in 2022, then soared by 36.65% to $1.6 billion in 2023, then advanced by 20.44% to $1.9 billion in 2024, then increased by 1.33% to $2.0 billion in 2025, then dropped by 0.14% to $2.0 billion in 2026.
• Business Quant data shows BEIGF's Non-Current Assets at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $2.0 billion in Q3 2025.